Panadol Extra with Optizorb Formulation³

• Always read the product label before use and do not exceed the recommended dose. 

• Panadol rarely has side effects when taken at the recommended dose, however if you do experience any side effects as a result of taking Panadol Extra Tablets, stop use immediately and consult a healthcare professional.   

• Panadol Extra with OPTIZORB contain paracetamol. You should not use them with any other products that contain paracetamol, as combining paracetamol-based medicines may lead to an overdose. Always read the product label on any other medication you plan to take in combination with Panadol before use, and consult with a doctor or pharmacist to check that it is safe to do so.  

• Panadol Extra with OPTIZORB contain caffeine. Excessive intake of caffeine (e.g. coffee, tea and some canned drinks) should be avoided while taking Panadol Extra.

• Note that each Panadol Extra with OPTIZORB contain parahydroxybenzoates (sodium methyl, sodium ethyl, sodium propyl), which may cause allergic reactions. Ask a doctor or pharmacist before use if you are unsure about whether or not you should take Panadol.  

• Panadol Extra Tablets are not recommended for use in children aged under 12 years. Keep them out of sight and reach of children. 
  

Before taking Panadol Extra with Optizorb:

A. Do not take Panadol Extra with Optizorb:

If you have known or previous history of hypersensitivity to paracetamol, caffeine or any other ingredients.

B. Take special care with Panadol Extra with Optizorb:

• Paracetamol overdose may cause liver failure which can lead to liver transplant or death.
• Cases of paracetamol induced hepatotoxicity, including fatal cases, have been reported in patients taking paracetamol at doses within the therapeutic range. These cases were reported in patients with one or more risk factors for hepatotoxicity including low body weight (<50 Kg), renal and hepatic impairment, chronic alcoholism, concomitant intake of hepatotoxic drugs, sepsis and in acute and chronic malnutrition (low reserves of hepatic glutathione). Paracetamol should be administered with caution to patients with these risk factors.
• Caution is also advised in patients on concomitant treatment with drugs that induce hepatic enzymes and in conditions which may predispose to glutathione deficiency (see sections 4.2 and 4.9). In patients with glutathione depleted states such as sepsis; the use of paracetamol may increase the risk of metabolic acidosis.
• Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as those using maximum daily doses of paracetamol. Close monitoring, including measurement of urinary 5-oxoproline, is recommended.
• Doses of paracetamol should be reviewed at clinically appropriate intervals and patients should be monitored for emergence of new risk factors for hepatoxicity which may warrant dosage adjustment.
• Underlying liver disease increases the risk of paracetamol related liver damage.
• Patients who have been diagnosed with liver or kidney impairment must seek medical advice before taking this medication.
• Prolonged use except under medical supervision may be harmful.
• Do not exceed the stated dose.
• Take only when necessary.
• If symptoms persist for longer than 3 days, consult your doctor.
• Keep out of the sight and reach of children.